---
title: "editorial glp 1 agonists weight loss"
year: 2024
month: 10
journal: "American Family Physician"
volume: "109-110"
issue: "10"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-10-editorial-glp-1-agonists-weight-loss.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# editorial glp 1 agonists weight loss

Editorials


Prescribing GLP-1 Agonists for Weight Loss:​
Wrestling With Our Philosophical Angst
Madhuri Rao, MD;​Allen Shaughnessy, PharmD;​and Randi Sokol, MD, MPH, MMedEd




M         ultiple glucagon-like peptide-1 (GLP-1) agonist med-
          ications, created for the treatment of type 2 diabetes
mellitus, are now labeled for the treatment of obesity. By acti-
                                                                         more strength and substance.14 Patients with larger bodies are
                                                                         affected by weight-based marginalization driven by commercial
                                                                         and societal forces.15 Patients may be unable to detach from the
vating GLP-1 peptides, these medications affect body weight              societal discord they feel from being overweight.
in many ways, including inhibiting glucagon and stimulating                 Given the sociopolitical origins of our weight-focused cul-
insulin release, and resulting in an average loss of 5% to 15%           ture, how should we address our patients’ desires to achieve
of body weight sustainable for at least 12 months.1-3                    a certain weight, even if there is no strict medical need to
   Family physicians may feel angst when patients request these          do so?
medications, considering that weight and body mass index                    As with all shared decisions, we can start by providing
(BMI) are flawed health metrics, and the current societal desire         objective information and using a STEPS approach, which
for thinness has murky origins. However, weight stigma is also           outlines a medication’s safety, tolerability, effectiveness, price,
real and detrimental.4                                                   and simplicity.16 For example, the long-term effects of GLP-1
   Many physicians have been trained to think of obesity as a            agonists on the pancreas are unknown (safety). Adverse effects
disease and, therefore, inherently harmful.5,6 However, mortal-          can include nausea, vomiting, diarrhea, and bloating due to
ity is not correlated with BMI, and weight loss is not correlated        gastroparesis (tolerability). GLP-1 agonists’ effectiveness may
with improved health even in patients with diabetes and car-             be limited since most people regain weight when they stop
diovascular disease.7 Nearly all intentional weight loss results         taking the medication (effectiveness). These medications are
in eventual weight gain beyond baseline weight.8 Chronic                 expensive (price), and injections are more complex than oral
dieting and weight cycling can result in depression, increased           medications (simplicity).
blood pressure, eating disorders, and increased all-cause mortal-           We can also redirect the conversation toward health-
ity.9-12 Two people with the same BMI can have different health          promoting behaviors. Becausee patients often seek validation
behaviors, life experiences, and body compositions, resulting in         from physicians to lose weight, we can acknowledge their
vastly different health status and quality of life.13                    goal while emphasizing a more holistic approach to health,
   The cultural fear of weight gain and larger body size has             encouraging patients to engage in exercise they enjoy and eat
insidious origins. Larger bodies were assumed to be an attribute         nourishing foods that make them feel good and not deprived.
of people of color. They were associated with being “feminine”           We advocate for a Health at Every Size approach:​rather than
and “overly sensual” in the aftermath of the slave trade, and            focusing on changing weight, patients should embrace oppor-
colonialists purposely distanced themselves from indigenous              tunities to develop a patient-centered collaborative plan that
diets.14 The White European ideal of being “frail and delicate”          includes nourishment, intuitive eating, joyful movement, sleep,
and having “rational self-control” allowed women to distance             and stress reduction, which result in improved long-term health
themselves from the working class, who they saw as requiring             outcomes.17 Through these behaviors, patients reap the benefits
                                                                         of dietary variety and cardiovascular exercise while allowing
                                                                         their bodies to find their inherent homeostatic set points.18
   See related article at https://​w ww.aafp.org/pubs/afp/                  We must also empathize with patients experiencing weight-
   issues/2024/0800/obesity-management.html.                             based marginalization. Even without a medical need for weight
                                                                         loss, we can work with patients toward an informed approach
   MADHURI RAO, MD; ALLEN SHAUGHNESSY, PharmD;
                                                                         that respects their bodily autonomy and recognizes their soci-
   and RANDI SOKOL, MD, MPH, MMedEd, Tufts Family
                                                                         etal discord and experiences living in larger bodies. Prescribing
   Medicine Residency Program at Cambridge Health Alli-
                                                                         a GLP-1 agonist may be appropriate for these patients.
   ance, Malden, Massachusetts.
                                                                            Although patients will likely continue to request GLP-1 ago-
   Author disclosure:​No relevant financial relationships.               nists and other weight-loss remedies, we do not have to embrace
   Address correspondence to Randi Sokol, MD, MPH,                       a weight-centric approach. We can listen to patients, validat-
   MMedEd, at rsokol@​challiance.org.                                    ing their needs and goals. We can promote healthy behaviors
                                                                         and acknowledge the dissonance of living in a diet-entrenched

              Downloaded from the American Family Physician website at www.aafp.org/afp. Copyright © 2024 American Acad-
340 American Family Physician	                                                                           Volume 110, Number 4 • October 2024
              emy of Family Physicians. For the private, noncommercial use of one individual user of the website. All other rights
                           reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                                                                                                             EDITORIALS


society with the understanding that weight loss may not be                   8. Tomiyama AJ, Ahlstrom B, Mann T. Long‐term effects of dieting:​is
                                                                                weight loss related to health? Soc Personal Psychol Compass. 2013;​
the answer.
                                                                                7(12):​861-877.
                                                                              9. Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality
Editor’s Note:​Dr. Shaughnessy is an assistant medical editor for                with overweight and obesity using standard body mass index
                                                                                 categories:​a systematic review and meta-analysis. JAMA. 2013;​309(1):​
AFP.
                                                                                 71-82.
                                                                             10. Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated
REFERENCES                                                                       with underweight, overweight, and obesity. JAMA. 2005;​293(15):​
1. Bald E, Raber H. Semaglutide (Wegovy) for the treatment of obesity.           1861-1867.
   Am Fam Physician. 2023;​107(1):​90-91.                                    11. Stoll LC. Fat is a social justice issue, too. Humanity Soc. 2019;​43(4):​
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al.;​SURMOUNT-1                        421-441.
   Investigators. Tirzepatide once weekly for the treatment of obesity.      12. Diaz VA, Mainous AG III, Everett CJ. The association between weight
   N Engl J Med. 2022;​387(3):​205-216.                                          fluctuation and mortality:​results from a population-based cohort
3. Whitten JS. Liraglutide (Saxenda) for weight loss. Am Fam Physician.          study. J Community Health. 2005;​30(3):​153-165.
   2016;​94(2):​161-166.                                                     13. Prillaman M. Why BMI is flawed - and how to redefine obesity. Nature.
4. Flegal KM, Ioannidis JPA, Doehner W. Flawed methods and                       2023;​622(7982):​232-233.
   inappropriate conclusions for health policy on overweight and obesity:​   14. Strings S. Fearing the Black Body:​The Racial Origins of Fat Phobia. New
   the Global BMI Mortality Collaboration meta-analysis. J Cachexia              York University Press;​2019.
   Sarcopenia Muscle. 2019;​10(1):​9-13.                                     15. Deetz SA. Democracy in an Age of Corporate Colonization:​
5. Moynihan R. Obesity task force linked to WHO takes “millions” from            Developments in Communication and the Politics of Everyday Life.
   drug firms. BMJ. 2006;​332(7555):​1412.                                       State University of New York Press;​1992.
6. Pollack A. AMA recognizes obesity as a disease. The New York Times.       16. Shaughnessy AF. STEPS drug updates. Am Fam Physician. 2003;​68(12):​
   June 18, 2013. Accessed January 20, 2024. https://​w ww.nytimes.              2342-2348.
   com/2013/06/19/business/ama-recognizes-obesity-as-a-disease.              17. Association for Size Diversity and Health. Health at Every Size
   html                                                                          principles. Accessed January 20, 2024. https://​asdah.org/haes
7. Simonsen MK, Hundrup YA, Obel EB, et al. Intentional weight loss and      18. Ganipisetti VM, Bollimunta P. Obesity and set-point theory. In:​
   mortality among initially healthy men and women. Nutr Rev. 2008;​             StatPearls. April 25, 2023. Accessed January 27, 2024. https://​w ww.
   66(7):​375-386.                                                               ncbi.nlm.nih.gov/books/NBK592402/ ■




    Learn on the Go
    with AFP Podcast
    Get your clinical
    updates on the go.
    Listen to family physicians and
    residents discuss key evidence-
    based learning points from the
    latest issue of American Family
    Physician (AFP).




                                                                                    aafp.org/afp/podcast

 AFP Podcast commute_no bleed_HfHorz_7x4.5_0924.indd 2                                                                                        9/16/24 10:46 AM
October 2024 • Volume 110, Number 4                                                                                     American Family Physician 341
